SCHEMBL4157903

SCHEMBL4157903

CN(Cc1ccccc1)S(=O)(=O)c1ccc2[nH]c(=O)c3[nH]cc(CCC(=O)O)c3c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
TP53 P04637 1/20 0.48
RXFP1 Q9HBX9 2/20 0.48
POLB P06746 1/20 0.48
KDM4E B2RXH2 7/20 0.44
ALDH1A1 P00352 6/20 0.43
HPGD P15428 4/20 0.43
HSD17B10 Q99714 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
USP2 O75604 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GLA P06280 1/20 0.41
PKM P14618 1/20 0.40
MAPK1 P28482 1/20 0.40
LMNA P02545 2/20 0.40
HTR2C P28335 1/20 0.40
CDK4 P11802 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4162755 0.92 ALDH1A1 (0.44) MAPTTP53RXFP1POLBKDM4E
SCHEMBL4162942 0.88 KDM4E (0.44) MAPTTP53RXFP1KDM4EALDH1A1
SCHEMBL4166925 0.87 USP2 (0.45) MAPTRXFP1POLBKDM4EALDH1A1
SCHEMBL3251841 0.85 MAPT (0.51) MAPTTP53RXFP1POLBKDM4E
SCHEMBL4162519 0.84 DAO (0.42) MAPTPOLBKDM4EALDH1A1HPGD
SCHEMBL4169887 0.84 KDM4E (0.55) MAPTTP53RXFP1POLBKDM4E
SCHEMBL4163996 0.82 GAA (0.46) MAPTTP53RXFP1KDM4EALDH1A1
SCHEMBL4162711 0.82 PTGDR2 (0.38) MAPTKDM4EALDH1A1HPGDHSD17B10
SCHEMBL4155191 0.82 HPGD (0.42) MAPTKDM4EALDH1A1HPGDCDK4
SCHEMBL4157685 0.81 KDM4E (0.48) MAPTTP53RXFP1POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 MAPT 734/4885TP53 637/4885RXFP1 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.